Immunotherapy in Prostate Cancer

Ilya Sobol, R. H. Thompson, Haidong M Dong, Christopher Krco, Eugene D Kwon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. Multiple molecular targets and clinical agents have been developed recently, particularly in the field of metastatic adenocarcinoma of the prostate. Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized trial underway after a phase II trial showed an improvement in overall survival. Interestingly, both these agents showed improvement in overall survival with no measurable change in disease state, leading to significant controversy as the utility of these agents in prostate cancer. Ipilimumab revealed a benefit for a sub-cohort of men in a post-docetaxel group and is currently undergoing investigation in a pre-docetaxel group. There are a number of other targets such as PD-1 which have shown effectiveness in other neoplasms that will likely be investigated in the future for use in prostate cancer.

Original languageEnglish (US)
Pages (from-to)1-5
Number of pages5
JournalCurrent Urology Reports
Volume16
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

docetaxel
Immunotherapy
Prostatic Neoplasms
Survival
Prostate
Neoplasms
Adenocarcinoma
Therapeutics

Keywords

  • Immunotherapy
  • Ipilimumab
  • Prostate cancer
  • PSA-TRICOM

ASJC Scopus subject areas

  • Urology

Cite this

Immunotherapy in Prostate Cancer. / Sobol, Ilya; Thompson, R. H.; Dong, Haidong M; Krco, Christopher; Kwon, Eugene D.

In: Current Urology Reports, Vol. 16, No. 6, 01.06.2015, p. 1-5.

Research output: Contribution to journalArticle

Sobol, Ilya ; Thompson, R. H. ; Dong, Haidong M ; Krco, Christopher ; Kwon, Eugene D. / Immunotherapy in Prostate Cancer. In: Current Urology Reports. 2015 ; Vol. 16, No. 6. pp. 1-5.
@article{763530c88ac046aa93a1c665f95e6da8,
title = "Immunotherapy in Prostate Cancer",
abstract = "Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. Multiple molecular targets and clinical agents have been developed recently, particularly in the field of metastatic adenocarcinoma of the prostate. Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized trial underway after a phase II trial showed an improvement in overall survival. Interestingly, both these agents showed improvement in overall survival with no measurable change in disease state, leading to significant controversy as the utility of these agents in prostate cancer. Ipilimumab revealed a benefit for a sub-cohort of men in a post-docetaxel group and is currently undergoing investigation in a pre-docetaxel group. There are a number of other targets such as PD-1 which have shown effectiveness in other neoplasms that will likely be investigated in the future for use in prostate cancer.",
keywords = "Immunotherapy, Ipilimumab, Prostate cancer, PSA-TRICOM",
author = "Ilya Sobol and Thompson, {R. H.} and Dong, {Haidong M} and Christopher Krco and Kwon, {Eugene D}",
year = "2015",
month = "6",
day = "1",
doi = "10.1007/s11934-015-0509-7",
language = "English (US)",
volume = "16",
pages = "1--5",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Immunotherapy in Prostate Cancer

AU - Sobol, Ilya

AU - Thompson, R. H.

AU - Dong, Haidong M

AU - Krco, Christopher

AU - Kwon, Eugene D

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. Multiple molecular targets and clinical agents have been developed recently, particularly in the field of metastatic adenocarcinoma of the prostate. Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized trial underway after a phase II trial showed an improvement in overall survival. Interestingly, both these agents showed improvement in overall survival with no measurable change in disease state, leading to significant controversy as the utility of these agents in prostate cancer. Ipilimumab revealed a benefit for a sub-cohort of men in a post-docetaxel group and is currently undergoing investigation in a pre-docetaxel group. There are a number of other targets such as PD-1 which have shown effectiveness in other neoplasms that will likely be investigated in the future for use in prostate cancer.

AB - Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. Multiple molecular targets and clinical agents have been developed recently, particularly in the field of metastatic adenocarcinoma of the prostate. Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized trial underway after a phase II trial showed an improvement in overall survival. Interestingly, both these agents showed improvement in overall survival with no measurable change in disease state, leading to significant controversy as the utility of these agents in prostate cancer. Ipilimumab revealed a benefit for a sub-cohort of men in a post-docetaxel group and is currently undergoing investigation in a pre-docetaxel group. There are a number of other targets such as PD-1 which have shown effectiveness in other neoplasms that will likely be investigated in the future for use in prostate cancer.

KW - Immunotherapy

KW - Ipilimumab

KW - Prostate cancer

KW - PSA-TRICOM

UR - http://www.scopus.com/inward/record.url?scp=84928402716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928402716&partnerID=8YFLogxK

U2 - 10.1007/s11934-015-0509-7

DO - 10.1007/s11934-015-0509-7

M3 - Article

C2 - 25894495

AN - SCOPUS:84928402716

VL - 16

SP - 1

EP - 5

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 6

ER -